---
title: "聖諾醫藥 (02257.HK)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/02257.HK.md"
symbol: "02257.HK"
name: "聖諾醫藥"
industry: "生物技術"
---

# 聖諾醫藥 (02257.HK)

| Item | Detail |
|------|--------|
| Industry | 生物技術 |
| Location | 港股市場 |
| Website | [www.sirnaomics.com](https://www.sirnaomics.com) |

## Company Profile

Sirnaomics Ltd是一家投資控股公司。該公司及其子公司均為臨床階段生物技術公司,致力於開發和商業化核糖核酸幹擾(RNAi)技術及多種療法。該公司專注於發現和開發針對特定領域尚未滿足醫療需求的藥物。該公司主要臨床候選藥物包括STP705和STP707。STP705是一種多靶點siRNA療法,目前正在推進針對兩種腫瘤適應症的臨床開發:原位鱗狀細胞癌(isSCC)和基底細胞癌(BCC)。STP707是一種靜脈注射siRNA療法,目前正在進行針對多種實體瘤(包括結直腸癌、胰腺癌、肝癌和轉移性黑色素瘤)的I期臨床試驗。該公司正充分利用其雙重遞送平臺,包括多肽納米顆粒(PNP)和GalAhead...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-16T04:30:10.000Z

**Overall: C (0.55)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 37 / 53 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 38.86% |  |
| Net Profit YoY | 82.93% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | -19.14 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 768.63M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 7.39M |  |


**Multi Score**: C

#### Profit Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 575.13% | A |
| Profit Margin | -1476.92% | E |
| Gross Margin | 100.00% | A |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 38.86% | A |
| Net Profit YoY | 82.93% | A |
| Total Assets YoY | -38.05% | E |
| Net Assets YoY | -7.68% | D |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -6.77% | D |
| OCF YoY | 38.86% | A |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.03 | E |

#### Debt Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 189.65% | E |


```chart-data:radar
{
  "title": "Longbridge Financial Score - 聖諾醫藥",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "575.13%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-1476.92%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "38.86%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "82.93%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-38.05%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-7.68%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-6.77%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "38.86%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.03",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "E",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "189.65%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 百濟神州 (HK.6160) | C | A | B | C | A | B |
| 02 | 信達生物 (HK.1801) | B | A | C | B | A | B |
| 03 | 三生制藥 (HK.1530) | A | B | C | A | C | B |
| 04 | 百奧賽圖-B (HK.2315) | A | A | C | D | B | B |
| 05 | 和鉑醫藥-B (HK.2142) | A | A | C | B | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -7.11 | 28/70 | - | - | - |
| PB | -19.48 | 68/70 | 192.08 | 173.32 | 168.35 |
| PS (TTM) | 56.71 | 46/70 | 78.64 | 60.81 | 27.43 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-06-04T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 7.30 |
| Highest Target | 72.11 |
| Lowest Target | 72.11 |

## References

- [Company Overview](https://longbridge.com/en/quote/02257.HK/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/02257.HK/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/02257.HK/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.